Lupin Limited — Others, 18-12-2024: Rumour Verification - Regulation 30(11)

Lupin Limited has announced a board meeting to discuss its financial results for the quarter and half-year. The company confirmed receiving approval from the U.S. FDA for its generic version of Descovy® Tablets, which is significant as it positions Lupin as one of the first applicants eligible for 180 days of shared generic exclusivity. This approval is expected to enhance the company's product portfolio and financial performance, particularly as the product will be manufactured at its Nagpur facility. Investor sentiment could shift positively due to the potential for increased market share in the HIV treatment segment.